{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:10:32Z","timestamp":1740107432646,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005296","name":"Universit\u00e4tsklinikum Regensburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005296","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Die Lupusnephritis stellt die h\u00e4ufigste Manifestation eines systemischen Lupus an den soliden Organen dar und geht mit einem erh\u00f6hten Risiko f\u00fcr eine chronische Niereninsuffizienz einher. Das gleichzeitige Auftreten einer Lupusnephritis mit einer thrombotischen Mikroangiopathie wird als selten beschrieben, impliziert jedoch das Risiko fataler Organdysfunktionen. Wir berichten von drei Patienten, bei denen diese beiden Krankheitsentit\u00e4ten parallel auftraten und eine intensivierte immunsuppressive Therapie auch mittels Komplementblockade notwendig machten.<\/jats:p>","DOI":"10.1007\/s00393-024-01489-9","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T14:02:41Z","timestamp":1709647361000},"page":"675-678","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lupusnephritis und assoziierte thrombotische Mikroangiopathie","Lupus nephritis and associated thrombotic microangiopathy"],"prefix":"10.1007","volume":"83","author":[{"given":"Antonia","family":"Schuster","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Banas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Bergler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"issue":"2","key":"1489_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/rheumatology\/kev311","volume":"55","author":"JG Hanly","year":"2016","unstructured":"Hanly\u00a0JG, O\u2019Keeffe\u00a0AG, Su\u00a0L et\u00a0al (2016) The frequency and outcome of lupus nephritis: Results from an international inception cohort study. Rheumatology 55(2):252\u2013262. https:\/\/doi.org\/10.1093\/rheumatology\/kev311","journal-title":"Rheumatology"},{"issue":"6","key":"1489_CR2","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/art.39594","volume":"68","author":"MG Tektonidou","year":"2016","unstructured":"Tektonidou\u00a0MG, Dasgupta\u00a0A, Ward\u00a0MM (2016) Risk of end-stage renal disease in patients with lupus nephritis, 1971\u20132015: a\u00a0systematic review and Bayesian meta-analysis. Arthritis Rheumatol 68(6):1432\u20131441. https:\/\/doi.org\/10.1002\/art.39594","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"1489_CR3","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1056\/NEJMra1312353","volume":"371","author":"JN George","year":"2014","unstructured":"George\u00a0JN, Nester\u00a0CM (2014) Syndromes of thrombotic microangiopathy. N\u00a0Engl J Med 371(7):654\u2013666. https:\/\/doi.org\/10.1056\/NEJMra1312353","journal-title":"N Engl J Med"},{"issue":"2","key":"1489_CR4","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/jth.13571","volume":"15","author":"M Scully","year":"2017","unstructured":"Scully\u00a0M, Cataland\u00a0S, Coppo\u00a0P et\u00a0al (2017) Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J\u00a0Thromb Haemost 15(2):312\u2013322. https:\/\/doi.org\/10.1111\/jth.13571","journal-title":"J Thromb Haemost"},{"issue":"3","key":"1489_CR5","first-page":"169","volume":"15","author":"X Chen","year":"2021","unstructured":"Chen\u00a0X, Cheng\u00a0W, Wang\u00a0G et\u00a0al (2021) Clinical characteristics and prognosis of renal thrombotic microangiopathy in lupus nephritis. Iran J Kidney Dis 15(3):169\u2013176","journal-title":"Iran J Kidney Dis"},{"issue":"1","key":"1489_CR6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12882-021-02293-2","volume":"22","author":"MJ Kim","year":"2021","unstructured":"Kim\u00a0MJ, Lee\u00a0H, Kim\u00a0YH et\u00a0al (2021) Eculizumab therapy on a\u00a0patient with co-existent lupus nephritis and C3 mutation-related atypical haemolytic uremic syndrome: A\u00a0case report. BMC Nephrol 22(1):86. https:\/\/doi.org\/10.1186\/s12882-021-02293-2","journal-title":"BMC Nephrol"},{"issue":"10","key":"1489_CR7","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1177\/09612033221106301","volume":"31","author":"D Massicotte-Azarniouch","year":"2022","unstructured":"Massicotte-Azarniouch\u00a0D, Kotzen\u00a0E, Todd\u00a0S, Hu\u00a0Y, Hogan\u00a0SL, Jain\u00a0K (2022) Kidney thrombotic microangiopathy in lupus nephritis: Impact on treatment and prognosis. Lupus 31(10):1175\u20131185. https:\/\/doi.org\/10.1177\/09612033221106301","journal-title":"Lupus"},{"issue":"2","key":"1489_CR8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000492033","volume":"48","author":"S Olson","year":"2018","unstructured":"Olson\u00a0S, Lu\u00a0E, Sulpizio\u00a0E, Shatzel\u00a0J, Rueda\u00a0J, DeLoughery\u00a0T (2018) When to stop eculizumab in complement-mediated thromboticmicroangiopathies. Am J Nephrol 48(2):96\u2013107","journal-title":"Am J Nephrol"},{"issue":"16","key":"1489_CR9","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1182\/bloodadvances.2018019596","volume":"2","author":"MH Park","year":"2018","unstructured":"Park\u00a0MH, Caselman\u00a0N, Ulmer\u00a0S, Weitz\u00a0IC (2018) Complement-mediated thrombotic microangiopathy associated with lupus nephritis. Blood Adv 2(16):2090. https:\/\/doi.org\/10.1182\/bloodadvances.2018019596","journal-title":"Blood Adv"},{"issue":"1","key":"1489_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1159\/000512227","volume":"11","author":"EA Torres","year":"2021","unstructured":"Torres\u00a0EA, Chang\u00a0Y, Desai\u00a0S et\u00a0al (2021) Complement-mediated thrombotic microangiopathy associated with lupus nephritis treated with eculizumab: a\u00a0case report. Case Rep Nephrol Dial 11(1):95\u2013102. https:\/\/doi.org\/10.1159\/000512227","journal-title":"Case Rep Nephrol Dial"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01489-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-024-01489-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01489-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T11:03:55Z","timestamp":1729076635000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-024-01489-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1489"],"URL":"https:\/\/doi.org\/10.1007\/s00393-024-01489-9","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"type":"print","value":"0340-1855"},{"type":"electronic","value":"1435-1250"}],"subject":[],"published":{"date-parts":[[2024,3,5]]},"assertion":[{"value":"17 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Schuster, B.\u00a0Banas und T.\u00a0Bergler geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}